Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Maop Cpd
2. Methyl 5-aminolevulinate
3. Methyl Aminolaevulinate
4. Metvix
1. Metvix
2. 33320-16-0
3. Methyl 5-aminolevulinate
4. Methyl 5-amino-4-oxopentanoate
5. Aminolevulinic Acid Methyl Ester
6. 5-aminolevulinic Acid Methyl Ester
7. Methyl Aminolaevulinate
8. Methyl Delta-aminolevulinate
9. Pentanoic Acid, 5-amino-4-oxo-, Methyl Ester
10. D-aminolevulinicacidmethylesterhydrochloride
11. 585nm85kym
12. Chebi:724125
13. Maop Cpd
14. Ncgc00018251-03
15. Unii-585nm85kym
16. Levulinic Acid, 5-amino-, Methyl Ester
17. Methyl5-amino-4-oxopentanoate
18. Methylaminolevulinate
19. Methyl-aminolevulinate
20. Methyl-5-aminolevulinate
21. Schembl8521
22. 5-aminolavulinsauremethylester
23. Chembl1096562
24. Dtxsid3048570
25. Methyl Aminolevulinate [mi]
26. Hy-a0169
27. Zinc1909090
28. Methyl Aminolevulinate [vandf]
29. Akos006220489
30. Db00992
31. Methyl Aminolevulinate [who-dd]
32. Ncgc00018251-01
33. Ncgc00018251-02
34. Ncgc00018251-04
35. Ncgc00018251-05
36. Da-06782
37. 5-amino-4-oxo-pentanoic Acid Methyl Ester
38. Cs-0017508
39. Ft-0760150
40. D08204
41. Q619603
| Molecular Weight | 145.16 g/mol |
|---|---|
| Molecular Formula | C6H11NO3 |
| XLogP3 | -1 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 5 |
| Exact Mass | 145.07389321 g/mol |
| Monoisotopic Mass | 145.07389321 g/mol |
| Topological Polar Surface Area | 69.4 Ų |
| Heavy Atom Count | 10 |
| Formal Charge | 0 |
| Complexity | 133 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For topical use, in combination with 570 to 670 nm wavelength red light illumination, in the treatment of non-hyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used in conjunction with lesion preparation (debridement using a sharp dermal curette).
FDA Label
After topical application of methyl aminolevulinate, porphyrins will accumulate intracellularly in the treated skin lesions. The intracellular porphyrins (including PpIX) are photoactive, fluorescing compounds and, upon light activation in the presence of oxygen, singlet oxygen is formed which causes damage to cellular compartments, in particular the mitochondria. Light activation of accumulated porphyrins leads to a photochemical reaction and thereby phototoxicity to the light-exposed target cells.
Photosensitizing Agents
Drugs that are pharmacologically inactive but when exposed to ultraviolet radiation or sunlight are converted to their active metabolite to produce a beneficial reaction affecting the diseased tissue. These compounds can be administered topically or systemically and have been used therapeutically to treat psoriasis and various types of neoplasms. (See all compounds classified as Photosensitizing Agents.)
L01XD03
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01X - Other antineoplastic agents
L01XD - Sensitizers used in photodynamic/radiation therapy
L01XD03 - Methyl aminolevulinate
Absorption
In vitro, after 24 hours the mean cumulative absorption through human skin was 0.26% of the administered dose.
Photosensitization following application of methyl aminolevulinate cream occurs through the metabolic conversion of methyl aminolevulinate (prodrug) to photoactive porphyrins (PAP), which accumulates in the skin lesions to which the cream has been applied. When exposed to light of appropriate wavelength and energy, the accumulated photoactive porphyrins produce a photodynamic reaction, resulting in a cytotoxic process dependent upon the simultaneous presence of oxygen. The absorption of light results in an excited state of porphyrin molecules, and subsequent spin transfer from photoactive porphyrins to molecular oxygen generates singlet oxygen, which can further react to form superoxide and hydroxyl radicals.
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
ABOUT THIS PAGE
87
PharmaCompass offers a list of Methyl Aminolevulinate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Methyl Aminolevulinate manufacturer or Methyl Aminolevulinate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Methyl Aminolevulinate manufacturer or Methyl Aminolevulinate supplier.
PharmaCompass also assists you with knowing the Methyl Aminolevulinate API Price utilized in the formulation of products. Methyl Aminolevulinate API Price is not always fixed or binding as the Methyl Aminolevulinate Price is obtained through a variety of data sources. The Methyl Aminolevulinate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Methyl Aminolevulinate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Methyl Aminolevulinate, including repackagers and relabelers. The FDA regulates Methyl Aminolevulinate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Methyl Aminolevulinate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Methyl Aminolevulinate supplier is an individual or a company that provides Methyl Aminolevulinate active pharmaceutical ingredient (API) or Methyl Aminolevulinate finished formulations upon request. The Methyl Aminolevulinate suppliers may include Methyl Aminolevulinate API manufacturers, exporters, distributors and traders.
Methyl Aminolevulinate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Methyl Aminolevulinate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Methyl Aminolevulinate GMP manufacturer or Methyl Aminolevulinate GMP API supplier for your needs.
A Methyl Aminolevulinate CoA (Certificate of Analysis) is a formal document that attests to Methyl Aminolevulinate's compliance with Methyl Aminolevulinate specifications and serves as a tool for batch-level quality control.
Methyl Aminolevulinate CoA mostly includes findings from lab analyses of a specific batch. For each Methyl Aminolevulinate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Methyl Aminolevulinate may be tested according to a variety of international standards, such as European Pharmacopoeia (Methyl Aminolevulinate EP), Methyl Aminolevulinate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Methyl Aminolevulinate USP).
